Targeted Oncology

Scope & Guideline

Advancing cancer care through targeted research.

Introduction

Welcome to your portal for understanding Targeted Oncology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1776-2596
PublisherSPRINGER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2006 to 2024
AbbreviationTARGET ONCOL / Target. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

Targeted Oncology is dedicated to the exploration and dissemination of cutting-edge research in the field of cancer treatment, specifically focusing on targeted therapies and precision medicine. The journal aims to provide a comprehensive platform for the publication of studies that enhance the understanding of molecular mechanisms of cancer, evaluate the efficacy and safety of novel therapies, and investigate real-world clinical outcomes.
  1. Targeted Therapies in Oncology:
    The journal emphasizes the development and application of targeted therapies, including small molecules, monoclonal antibodies, and antibody-drug conjugates, for various malignancies.
  2. Molecular Characterization of Tumors:
    Research focusing on the molecular and genetic profiling of tumors to identify actionable mutations and guide treatment decisions is a key area of focus.
  3. Real-World Evidence and Outcomes:
    Targeted Oncology publishes studies that provide insights into real-world treatment patterns, patient outcomes, and the effectiveness of therapies in diverse populations.
  4. Clinical Trials and Drug Development:
    The journal includes reports on clinical trials, particularly phase 1 and 2 studies that assess the safety and efficacy of new agents, as well as combination therapies.
  5. Immunotherapy and Combination Approaches:
    Research examining the intersection of immunotherapy with targeted therapies, including immune checkpoint inhibitors and their role in enhancing treatment outcomes.
  6. Emerging Biomarkers and Predictive Models:
    Studies identifying new biomarkers that predict responses to therapy and the development of prognostic models are central to the journal's aims.
Targeted Oncology has seen the emergence of several trending themes reflecting the latest advancements and shifts in cancer research priorities. These themes highlight the journal's commitment to addressing current challenges and innovations in the field.
  1. Integrative Approaches to Precision Medicine:
    There is a growing trend toward integrating genomic, transcriptomic, and proteomic data to develop personalized treatment strategies tailored to individual patients.
  2. Real-World Evidence Studies:
    An increase in real-world evidence studies showcasing treatment effectiveness, patient adherence, and outcomes in routine clinical practice reflects the journal's focus on practical applications of research.
  3. Biomarker-Driven Therapy:
    Emerging research centers on identifying and validating biomarkers that guide therapy selection, particularly in the context of targeted and immunotherapies.
  4. Combination Therapies:
    The exploration of combination therapies that leverage both targeted and immunotherapeutic agents is gaining prominence, underscoring the complexity of cancer treatment.
  5. Patient-Centric Research:
    There is an increased focus on patient-reported outcomes, quality of life studies, and the psychosocial aspects of cancer treatment, reflecting a holistic approach to oncology.

Declining or Waning

As the field of oncology evolves, certain research themes within Targeted Oncology have begun to show a decline in frequency and prominence. These waning scopes reflect shifts in research focus and the introduction of newer methodologies and treatment paradigms.
  1. Traditional Chemotherapy:
    There is a noticeable decline in publications centered around traditional chemotherapy regimens as the focus shifts toward targeted therapies and immunotherapy.
  2. Single-Agent Studies:
    Research exclusively investigating the efficacy of single-agent therapies is less prevalent as combination therapies gain more traction in clinical settings.
  3. General Cancer Epidemiology:
    While still important, broad epidemiological studies without a targeted focus on molecular mechanisms or specific therapies have become less emphasized.
  4. Non-Molecularly Targeted Treatment Strategies:
    The emphasis on non-targeted treatment strategies is decreasing as precision medicine and personalized therapy approaches dominate the landscape.
  5. Basic Science without Clinical Relevance:
    Studies that do not bridge laboratory research with clinical implications are less frequently published, as there is a stronger push for translational research.

Similar Journals

Therapeutic Advances in Medical Oncology

Catalyzing collaboration for improved cancer outcomes.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Surgical Oncology Clinics of North America

Innovative Insights for Surgical Excellence
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

World Journal of Clinical Oncology

Illuminating the Path to Oncology Excellence
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

International Cancer Conference Journal

Exploring New Horizons in Cancer Treatment and Prevention
Publisher: SPRINGER INT PUBL AGISSN: 2192-3183Frequency: 4 issues/year

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.

JCO Precision Oncology

Empowering Cancer Research with Tailored Therapies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Future Oncology

Empowering oncology through multidisciplinary insights.
Publisher: FUTURE MEDICINE LTDISSN: 1479-6694Frequency: 40 issues/year

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

npj Precision Oncology

Bridging Science and Clinical Practice in Cancer Research
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

Oncologie

Illuminating the path to effective cancer prevention and diagnosis.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Thoracic Cancer

Fostering collaboration for lung cancer solutions.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

SEMINARS IN ONCOLOGY

Transforming Cancer Research into Clinical Practice
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0093-7754Frequency: 6 issues/year

SEMINARS IN ONCOLOGY is a premier journal in the field of oncology, published by W B Saunders Co-Elsevier Inc. With its ISSN 0093-7754 and E-ISSN 1532-8708, this esteemed publication has been contributing significantly to cancer research and education since its inception in 1974. The journal currently holds a distinguished position in the academic landscape, ranking in the Q1 category for Hematology and Q2 for Oncology, and featured prominently in Scopus rankings—34th out of 137 in Medicine Hematology, and 108th out of 404 in Medicine Oncology. SEMINARS IN ONCOLOGY aims to disseminate cutting-edge research, critical reviews, and innovative treatment approaches, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to the fight against cancer. Although not an Open Access journal, it maintains a commitment to high-quality, peer-reviewed content, further solidifying its role as a vital reference point in oncological studies. The journal serves as a crucial platform for the exchange of knowledge, insights, and advancements that shape the future of cancer care.